Capricor Therapeutics (CAPR) Enterprise Value (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Enterprise Value of -$278.6 million for Q1 2026, down 92.44% year-over-year from -$3.7 billion in Q1 2025, and up 12.42% quarter-over-quarter from -$318.1 million in Q4 2025.
Capricor Therapeutics (CAPR) Enterprise Value (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$278.6 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 92.44% year-over-year to -$278.6 million; the TTM figure through Mar 2026 stood at -$278.6 million (down 92.44% YoY), while the FY2025 annual figure was -$318.1 million, down 109.96% from the prior year.
- Enterprise Value for Q1 2026 stood at -$278.6 million, up from -$318.1 million in the prior quarter.
- The five-year high for Enterprise Value was -$28.5 million in Q3 2023, with the low at -$318.1 million in Q4 2025.
- The 5-year median for Enterprise Value is -$51.4 million (2022), against an average of -$95.1 million.
- The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 38.81% in 2023, then sank 316.81% in 2025.
- Capricor Therapeutics' Enterprise Value stood at -$41.4 million in 2022, then climbed by 4.67% to -$39.5 million in 2023, then sank by 283.7% to -$151.5 million in 2024, then tumbled by 109.96% to -$318.1 million in 2025, then advanced by 12.42% to -$278.6 million in 2026.
- Business Quant data shows CAPR's Enterprise Value at -$278.6 million in Q1 2026, -$318.1 million in Q4 2025, and -$98.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -278.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278.61 Mn |
| Dec 31, 2025 | -318.13 Mn |
| Sep 30, 2025 | -98.57 Mn |
| Jun 30, 2025 | -122.80 Mn |
| Mar 31, 2025 | -144.78 Mn |
| Dec 31, 2024 | -151.52 Mn |
| Sep 30, 2024 | -85.03 Mn |
| Jun 30, 2024 | -29.46 Mn |
| Mar 31, 2024 | -39.92 Mn |
| Dec 31, 2023 | -39.49 Mn |
| Sep 30, 2023 | -28.52 Mn |
| Jun 30, 2023 | -37.79 Mn |
| Mar 31, 2023 | -45.17 Mn |
| Dec 31, 2022 | -41.42 Mn |
| Sep 30, 2022 | -46.61 Mn |
| Jun 30, 2022 | -51.42 Mn |
| Mar 31, 2022 | -58.30 Mn |
| Dec 31, 2021 | -34.89 Mn |
| Sep 30, 2021 | -40.80 Mn |
| Jun 30, 2021 | -38.10 Mn |